Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors

被引：1
|
作者：
Smith, Katherine E. R. [1 ,2 ]
Markovic, Svetomir N. [1 ]
机构：
[1] Mayo Clin, Dept Oncol, Rochester, MN USA
[2] Mayo Clin, Dept Oncol, 200,1st St SW, Rochester, MN 55905 USA
来源：
CLINICAL CHEMISTRY | 2024年 / 70卷 / 01期
关键词：
CTLA-4; BLOCKADE;
D O I：
10.1093/clinchem/hvad128
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [21] RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN PATIENTS WITH MICROSATELLITE INSTABLE AND HIGH TUMOR MUTATIONAL BURDEN PROSTATE CANCER
    Lenis, Andrew T.
    Ravichandran, Vignesh
    Hong Truong
    Reisz, Peter
    Nweji, Barbara
    Autio, Karen
    Morris, Michael
    Slovin, Susan
    Vargas, Hebert Alberto
    Laudone, Vincent
    Ehdaie, Behfar
    Reuter, Victor
    Viale, Agnes
    Schultz, Nikolaus
    Gopalan, Anuradha
    Donoghue, Mark
    Stopsack, Konrad
    Solit, David
    Abida, Wassim
    JOURNAL OF UROLOGY, 2021, 206 : E411 - E411
  • [22] The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
    Cortellini, Alessio
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
  • [23] Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
    Karn, T.
    Denkert, C.
    Weber, K. E.
    Holtrich, U.
    Hanusch, C.
    Sinn, B., V
    Higgs, B. W.
    Jank, P.
    Sinn, H. P.
    Huober, J.
    Becker, C.
    Blohmer, J-U
    Marme, F.
    Schmitt, W. D.
    Wu, S.
    van Mackelenbergh, M.
    Mueller, V
    Schem, C.
    Stickeler, E.
    Fasching, P. A.
    Jackisch, C.
    Untch, M.
    Schneeweiss, A.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1216 - 1222
  • [24] TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE REPLICATION REPAIR DEFICIENCY AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION
    Campbell, Brittany B.
    Light, Nicholas
    Fabrizio, David
    Bouffet, Eric
    Larouche, Valerie
    Samuel, David
    Stearns, Duncan
    Cole, Kristina A.
    Opocher, Enrico
    Thomas, Gregory
    Sabel, Magnus
    Dirks, Peter
    Taylor, Michael
    Malkin, David
    Albrecht, Steffen
    Dudley, Roy
    Jabado, Nada
    Hawkins, Cynthia
    Shlien, Adam
    Tabori, Uri
    NEURO-ONCOLOGY, 2018, 20 : 92 - 92
  • [25] Tumor mutational burden assessed by a targeted NGS assay to predict benefit from immune checkpoint inhibitors in non-small cell lung cancer
    Rothschild, Sacha
    Jermann, Philip
    Savic, Spasenija
    Mertz, Kirsten
    Zippelius, Alfred
    Quagliata, Luca
    Bubendorf, Lukas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports
    Moog, Sophie
    Lamartina, Livia
    Bani, Mohamed-Amine
    Al Ghuzlan, Abir
    Friboulet, Luc
    Italiano, Antoine
    Lacroix, Ludovic
    Vinay, Sophie Postel
    Tselikas, Lambros
    Deschamps, Frederic
    Bonnet, Baptiste
    Pani, Fabiana
    Baudin, Eric
    Hadoux, Julien
    THYROID, 2023, : 1368 - 1373
  • [27] Associations of genomic alteration, tumor mutational burden with PD-L1 expression and response to immune checkpoint inhibitors in Chinese lung patients
    Hu, Jing
    Li, Bixun
    Zou, Bing
    Wang, Senming
    Qiu, Ye
    Yan, Maolin
    Zeng, Zhiming
    Yang, Han
    Guan, Yan
    Zhang, Lei
    Chen, Wei
    Zhang, Yuan
    Mei, Lei
    Dong, Xiaowei
    Yao, Ming
    Wang, Kai
    CANCER RESEARCH, 2018, 78 (13)
  • [28] Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
    Chatrath, Ajay
    Ratan, Aakrosh
    Dutta, Anindya
    ISCIENCE, 2021, 24 (03)
  • [29] High Tumor Mutational Burden May Predict Improved Response to Immunotherapy in Head and Neck Cancer Patients
    Stewart, M.
    Reddy, C. A.
    Woody, N. M.
    Sussman, T.
    Yilmaz, E.
    Geiger, J. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E43 - E43
  • [30] High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
    Vareki, Saman Maleki
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
12345